Dr. Martens Plc (DE:3U2)
FRANKFURT:3U2
3U2 Stock Chart & Stats
€0.68
-€0.09(-9.68%)
At close: 4:00 PM EST
€0.68
-€0.09(-9.68%)
Day’s Range― - ―
52-Week Range€0.49 - €1.11
Previous CloseN/A
Volume0.00
Average Volume (3M)406.00
Market Cap
€693.07M
Enterprise Value€904.56M
Total Cash (Recent Filing)€95.70M
Total Debt (Recent Filing)€397.10M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
May 28, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding967,343,750
10 Day Avg. Volume2
30 Day Avg. Volume406
Financial Highlights & Ratios
PEG Ratio-1.17
Price to Book (P/B)1.34
Price to Sales (P/S)0.62
P/FCF Ratio2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.08Price Target Upside58.42% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€8.81M
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationSubstantial free cash flow and a robust operating cash flow to net income ratio provide durable funding for capex, store investment, inventory management, and shareholder returns. Strong cash conversion cushions the business against revenue volatility and funds strategic initiatives without relying on new borrowing.
High Gross Profit MarginA near-65% gross margin reflects strong product pricing, premium mix and brand strength across footwear categories. This structural margin advantage supports operating leverage and gives management flexibility to absorb cost inflation or invest in marketing while protecting long-term profitability if sales stabilize.
Reduced Net Debt And Manageable LeverageMaterial reduction in net bank debt and a mid-single leverage multiple improve financial resilience and borrowing headroom. Lower leverage increases capacity for strategic spending, supports liquidity through downturns and reduces refinancing risk, strengthening long-term capital structure stability.
Bears Say
Declining Revenue TrendPersistent negative revenue growth erodes scale benefits and makes fixed retail and distribution costs harder to cover. A shrinking top line limits ability to invest in product innovation, marketing and DTC growth, increasing dependence on margin gains or cost cuts to restore sustainable profitability.
Sharply Reduced Returns On EquityA collapse in ROE signals material deterioration in the company’s ability to generate shareholder returns from capital. This reflects reduced profitability and/or inefficient capital deployment, limiting investor confidence and indicating structural issues in converting brand strength into consistent earnings.
Regional/product Headwinds And TariffsWeakness in EMEA DTC and persistent issues in core categories like boots and sandals point to structural demand or assortment problems in key markets. Combined with tariff-driven cost pressure, these make margin recovery and consistent global growth harder without durable product or channel fixes.
Dr. Martens Plc News
3U2 FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
Dr. Martens Plc lowest stock price was €0.49 and its highest was €1.11 in the past 12 months.
What is Dr. Martens Plc’s market cap?
Dr. Martens Plc’s market cap is €693.07M.
When is Dr. Martens Plc’s upcoming earnings report date?
Dr. Martens Plc’s upcoming earnings report date is May 28, 2026 which is in 60 days.
How were Dr. Martens Plc’s earnings last quarter?
Dr. Martens Plc released its earnings results on Nov 20, 2025. The company reported -€0.01 earnings per share for the quarter, the consensus estimate of -€0.01 by €0.
Is Dr. Martens Plc overvalued?
According to Wall Street analysts Dr. Martens Plc’s price is currently Undervalued.
Does Dr. Martens Plc pay dividends?
Dr. Martens Plc does not currently pay dividends.
What is Dr. Martens Plc’s EPS estimate?
Dr. Martens Plc’s EPS estimate is 0.06.
How many shares outstanding does Dr. Martens Plc have?
Dr. Martens Plc has 967,343,750 shares outstanding.
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Dr. Martens Plc reported an EPS of -€0.01 in its last earnings report, expectations of -€0.01. Following the earnings report the stock price went up 0.564%.
Which hedge fund is a major shareholder of Dr. Martens Plc?
Currently, no hedge funds are holding shares in DE:3U2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Martens Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€1.08 (58.42% Upside)
€1.08 (58.42% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.87%
12-Months-Change
Fundamentals
Return on Equity
4.40%
Trailing 12-Months
Asset Growth
-7.19%
Trailing 12-Months
Company Description
Dr. Martens Plc
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.
3U2 Stock 12 Month Forecast
Average Price Target
€1.08
▲(58.42% Upside)
Technical Analysis
Options Prices
Currently, No data available
---